Please login to the form below

Not currently logged in
Email:
Password:

Medifacts announces USD 6.2m study award

Medifacts International, a US-based provider of non-invasive cardiac safety services, signs a four-year global study worth approximately USD 6.2m

Medifacts International, a US-based provider of non-invasive cardiac safety services, has signed a four-year global study worth approximately USD 6.2m.

The study is a late state registration programme sponsored by a major, but presently unnamed, biotechnology company.

Medifacts will provide comprehensive support for ECG, Holter, as well as ABPM endpoints including provision of equipment for digital collection of cardiac safety data that will be transferred to Medifacts for processing and analysis.

The company will use its proprietary web-based platform, WebHeart, which will enable efficient management of the data and provide a fully-digital environment for manual measurement and overread of ECGs and other cardiac safety and efficacy data while exceeding regulatory guidance and technical standards.

Michael Woehler, Medifacts' CEO, said: "The award represents an endorsement of the tremendous quality of our global services and a continuing vote of long-term confidence in the company by the sponsor community. Our WebHeart platform continues to set the global standard in cardiac safety data collection, management and submission, and we continue to consolidate our position as one of the top five global cardiac safety businesses.î

27th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics